Search research articles
Contact Us
Filters
Showing results (131-140 of 215) with videos related to
Page
of 22
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 27, 2011
Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure
Thomas Prébet, Steven D Gore, Benjamin Esterni, et al.
Cancer Chemotherapy and Pharmacology
|
February 25, 2025
A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumors
Susan C Scott, Anna Farago, W Victoria Lai, et al.
Blood Advances
|
May 21, 2020
Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States
Amer M Zeidan, Rong Wang, Xiaoyi Wang, et al.
Cancer Medicine
|
September 13, 2023
Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia
Nikolai A Podoltsev, Rong Wang, Rory M Shallis, et al.
British Journal of Haematology
|
February 9, 2010
Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C
Pierre Fenaux, Norbert Gattermann, John F Seymour, et al.
British Journal of Haematology
|
October 7, 2009
Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group
Mark R Litzow, Megan Othus, Larry D Cripe, et al.
Blood
|
August 5, 2009
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation
Maria E Figueroa, Lucy Skrabanek, Yushan Li, et al.
Blood Advances
|
August 19, 2018
Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia
Brian Ball, Rami S Komrokji, Lionel Adès, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 12, 2002
Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia
Steven D Gore, Li-Jun Weng, William D Figg, et al.
British Journal of Haematology
|
July 5, 2014
Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS
Amer M Zeidan, Ju-Whei Lee, Thomas Prebet, et al.
Page
of 22
Search research articles
Search
Showing results (131-140 of 215) with videos related to
Sort By:
Page
of 22
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 27, 2011
Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure
Thomas Prébet, Steven D Gore, Benjamin Esterni, et al.
Cancer Chemotherapy and Pharmacology
|
February 25, 2025
A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumors
Susan C Scott, Anna Farago, W Victoria Lai, et al.
Blood Advances
|
May 21, 2020
Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States
Amer M Zeidan, Rong Wang, Xiaoyi Wang, et al.
Cancer Medicine
|
September 13, 2023
Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia
Nikolai A Podoltsev, Rong Wang, Rory M Shallis, et al.
British Journal of Haematology
|
February 9, 2010
Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C
Pierre Fenaux, Norbert Gattermann, John F Seymour, et al.
British Journal of Haematology
|
October 7, 2009
Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group
Mark R Litzow, Megan Othus, Larry D Cripe, et al.
Blood
|
August 5, 2009
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation
Maria E Figueroa, Lucy Skrabanek, Yushan Li, et al.
Blood Advances
|
August 19, 2018
Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia
Brian Ball, Rami S Komrokji, Lionel Adès, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 12, 2002
Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia
Steven D Gore, Li-Jun Weng, William D Figg, et al.
British Journal of Haematology
|
July 5, 2014
Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS
Amer M Zeidan, Ju-Whei Lee, Thomas Prebet, et al.
Page
of 22